Comparison of the Efficacy between Conjugated Equine Estrogen versus Nonsteroidal Anti-inflammatory Drug for the Cessation of Uterine Bleeding among Contraceptive Implant Users: A randomized controlled trial
Article Sidebar
Main Article Content
Abstract
Objectives: To evaluate the effect of conjugated equine estrogen and nonsteroidal anti-inflammatory drugs on the controlling of abnormal uterine bleeding in hormonal subdermal implant users.
Materials and Methods: Between July 2022 and April 2023, participants with etonogestrel subdermal implants who complained of abnormal uterine bleeding were randomly allocated into two groups. The study group (n = 32) received 0.625 mg of conjugated equine estrogen orally twice a daily for five days, while the control group (n = 32) received 500 mg of mefenamic acid orally three times a daily for five days. The duration of bleeding cessation was evaluated.
Results: Baseline characteristics including age, BMI, duration of implant use, endometrial thickness, and pattern of bleeding were not statistically different in both groups. The duration of bleeding cessation was significantly shorter in the conjugated equine estrogen group (5.9 ± 3.4 vs 7.9 ± 3.9 days, mean difference 2.0 days (95%CI 0.01 to 0.02, p < 0.05)).
Conclusion: Conjugated equine estrogen was more effective than mefenamic acid in controlling abnormal uterine bleeding in etonogestrel subdermal implant use.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Croxatto HB. Progestin implants. Steroids 2000;65: 681-5.
Meirik O, Fraser IS, d’Arcangues C. Implantable contraceptives for women. Hum Reprod Update 2003;9:49-59.
Affandi B. Long-acting progestogens. Best Pract Res Clin Obstet Gynaecol 2002;16:169-79.
Archer DF, Philput CA, Weber ME. Management of irregular uterine bleeding and spotting associated with Norplant. Hum Reprod 1996;11(Suppl 2):24-30.
Friedlander E, Kaneshiro B. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obstet Gynecol Clin North Am 2015;42:593-603.
Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996;174:919- 22.
Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception 2006;73:253-6.
Schrager S. Abnormal uterine bleeding associated with hormonal contraception. Am Fam Physician 2002;65:2073-80.
Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai 2004;87:64–8.
Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception 1999;60:25-30.
Upawi SN, Ahmad MF, Abu MA, Ahmad S. Management of bleeding irregularities among etonogestrel implant users: Is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option? J Obstet Gynaecol Res 2020;46:479-84.
Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: A randomized controlled trial. Eur J Contracept Reprod Health Care 2016;21:361-6.
Belsey EM, Pinol EP. Menstrual bleeding patterns in untreated women. Contraception 1997;55:57–65.
Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133-7.
Intarangsri J,Puttasiri S. Bleeding Patterns after use of single-rod etonogestrel implant in postpartum adolescents. Thai J Obstet Gynaecol 2021; 29:322-30.
Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a -pictorial chart. Br J Obstet Gynaecol 1990;97:734-9.